Journal of Clinical Oncology, Vol 10, 1074-1077, Copyright © 1992 by American Society of Clinical Oncology
Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study
B Jeremic, D Grujicic, S Jevremovic, B Stanisavljevic, L Milojevic, L Djuric and L Mijatovic
Department of Oncology, University Hospital, Kragujevac, Yugoslavia.
PURPOSE: A phase II study that used combination chemotherapy with
carboplatin (CBDCA) and etoposide (VP 16) (CE) was performed on patients
with recurrent malignant glioma to investigate tumor control and toxicity.
PATIENTS AND METHODS: Thirty-eight patients were treated with CBDCA 300
mg/m2 on days 1 to 3 and VP 16 100 mg/m2 on days 1 to 5. A minimum of three
courses were required unless the patient had a rapid progression of disease
(PD). Courses were repeated every 4 weeks. RESULTS: We observed partial
responses (PRs) in eight of 38 patients (21%), stable disease (SD) in 12 of
38 (32%), whereas 18 of 38 (47%) patients had PD. The median time to tumor
progression (TTP) for PR and SD patients was 42.5 weeks, whereas the median
survival time (MST) for PR and SD patients was 47.5 weeks. Three groups of
toxicities were observed: hematologic, gastrointestinal, and hepatic. No
grade 4 Eastern Cooperative Oncology Group toxicity was observed.
CONCLUSIONS: This regimen has shown at least comparable results with other
series that used platinum-based agents. Further studies that use these
agents in various-dose schedules and drug combinations are warranted.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
N.-M. Tsai, S.-Z. Lin, C.-C. Lee, S.-P. Chen, H.-C. Su, W.-L. Chang, and H.-J. Harn
The Antitumor Effects of Angelica sinensis on Malignant Brain Tumors In vitro and In vivo
Clin. Cancer Res.,
May 1, 2005;
11(9):
3475 - 3484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Brandes, U. Basso, F. Vastola, A. Tosoni, L. M. Pasetto, A. Jirillo, S. Lonardi, M. K. Paris, H. Koussis, S. Monfardini, et al.
Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study
Ann. Onc.,
December 1, 2003;
14(12):
1727 - 1731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bello, G. Carrabba, C. Giussani, V. Lucini, F. Cerutti, F. Scaglione, J. Landre, M. Pluderi, G. Tomei, R. Villani, et al.
Low-dose Chemotherapy Combined with an Antiangiogenic Drug Reduces Human Glioma Growth in Vivo
Cancer Res.,
October 1, 2001;
61(20):
7501 - 7506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Cha, E. A. Knopp, G. Johnson, A. Litt, J. Glass, M. L. Gruber, S. Lu, and D. Zagzag
Dynamic Contrast-enhanced T2*-weighted MR Imaging of Recurrent Malignant Gliomas Treated with Thalidomide and Carboplatin
AJNR Am. J. Neuroradiol.,
May 1, 2000;
21(5):
881 - 890.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. S. Agarwala and J. M. Kirkwood
Temozolomide, a Novel Alkylating Agent with Activity in the Central Nervous System, May Improve the Treatment of Advanced Metastatic Melanoma
Oncologist,
April 1, 2000;
5(2):
144 - 151.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. Clarke, R. L. Basser, C. Underhill, P. Mitchell, J. Bartlett, L. Cher, M. Findlay, D. Dalley, M. Pell, M. Byrne, et al.
KRN8602 (MX2-Hydrochloride): An Active New Agent for the Treatment of Recurrent High-Grade Glioma
J. Clin. Oncol.,
August 1, 1999;
17(8):
2579 - 2579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Brandes, M. Ermani, S. Turazzi, E. Scelzi, F. Berti, P. Amista, A. Rotilio, C. Licata, and M. V. Fiorentino
Procarbazine and High-Dose Tamoxifen as a Second-Line Regimen in Recurrent High-Grade Gliomas: A Phase II Study
J. Clin. Oncol.,
February 1, 1999;
17(2):
645 - 645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. A. Levin
Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: The past decade and where we are heading
Neuro-oncol,
January 1, 1999;
1(1):
69 - 80.
[Abstract]
[PDF]
|
|
|
|
